Japan's Canon Aims to Buy Optopol Technology Of Poland For $45 Million
This article was originally published in PharmAsia News
Canon of Japan has begun the process of acquiring Optopol Technology of Poland, offering $45 million to shareholders for all shares
You may also be interested in...
The European Medicines Agency’s clinical data publication policy is on hold, but calls are growing for the regulator to start publishing trial data for COVID-19 treatments and vaccines as soon as they are authorized in the EU.
Facing the aftermath of coronavirus disruption and supply chain reorganization, executives of multinational drug firms in China say the government needs to do more to help address a flurry of issues laid bare by the public health crisis.
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.